These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 980217)

  • 1. Inhibitory effects of propranolol and oxprenolol on excitation induced by a MAO inhibitor and reserpine in the mouse.
    Delini-Stula A; Meier M
    Neuropharmacology; 1976 Jul; 15(7):383-8. PubMed ID: 980217
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of beta-adrenoceptor blocking properties of sotalol, oxprenolol, propranolol and pindolol on rabbit intestinal smooth muscle.
    Salimi M
    Pharmacology; 1975; 13(5):441-7. PubMed ID: 1802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of beta-adrenergic blocking activities of propranolol, isopropylmethoxamine, sotalol, practolol, alprenolol, pindolol, oxprenolol and D-32 in the atria and trachea of the guinea-pig.
    Horii D; Kawada T; Takeda K; Imai S
    Arzneimittelforschung; 1974 Sep; 24(9):1275-7. PubMed ID: 4154764
    [No Abstract]   [Full Text] [Related]  

  • 4. The haemodynamic effects of ( )-propranolol, dexpropranolol, oxprenolol, practolol and sotalol in anaesthetised dogs.
    Fitzgerald JD; Wale JL; Austin M
    Eur J Pharmacol; 1972 Jan; 17(1):123-34. PubMed ID: 4401429
    [No Abstract]   [Full Text] [Related]  

  • 5. Beta-adrenergic receptor blocking drugs in spontaneous hypertension.
    Levy JV
    Am J Med; 1976 Nov; 61(5):779-89. PubMed ID: 10729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.
    Leahey WJ; Neill JD; Varma MP; Shanks RG
    Eur J Clin Pharmacol; 1980 Jun; 17(6):419-24. PubMed ID: 7398733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effect of propranolol, oxprenolol and pindolol on neuromuscular blocking action of d-tubocurarine in man.
    Varma YS; Sharma PL; Singh HW
    Indian J Med Res; 1973 Sep; 61(9):1382-6. PubMed ID: 4779313
    [No Abstract]   [Full Text] [Related]  

  • 8. Class III action of beta-blocking agents.
    Taggart P; Donaldson R; Abed J; Nashat F
    Cardiovasc Res; 1984 Nov; 18(11):683-9. PubMed ID: 6149809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the effects of metipranolol, propranolol, alprenolol, oxprenolol, pindolol and practolol on the circulation in experimental animals.
    Trcka V; Vanĕcek M; Helfert I; Mácová S
    Acta Univ Carol Med (Praha); 1980; 26(5-6):239-58. PubMed ID: 6126104
    [No Abstract]   [Full Text] [Related]  

  • 10. Analysis of the hemodynamic action of beta-adrenolytics in narcotized cats.
    Górka Z
    Acta Med Pol; 1973; 14(1):7-26. PubMed ID: 4144422
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.
    McDevitt DG; Brown HC; Carruthers SG; Shanks RG
    Clin Pharmacol Ther; 1977 May; 21(5):556-66. PubMed ID: 15753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of reserpine on recovery rates after inhibition of monoamine oxidase in different regions of mouse brain.
    Hall TR; Yurgens PB; Figueroa HR
    Gen Pharmacol; 1984; 15(6):485-9. PubMed ID: 6526260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Editorial: Importance of cardioselectivity and sympaticomimetric potential of beta-blockers (author's transl)].
    Dubach UC
    Schweiz Rundsch Med Prax; 1975 Sep; 64(39):1239-41. PubMed ID: 241073
    [No Abstract]   [Full Text] [Related]  

  • 14. Protection against isoprenaline induced myocardial necroses by beta-adrenergic blocking agents.
    Kulig A; Kostka-Trabka E; Gryglewski R
    Pol J Pharmacol Pharm; 1973; 25(1):85-90. PubMed ID: 4149575
    [No Abstract]   [Full Text] [Related]  

  • 15. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
    Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
    J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective monoamine oxidase inhibitor drugs as aids in evaluating the role of type A and B enzymes.
    Fuentes JA; Neff NH
    Neuropharmacology; 1975 Nov; 14(11):819-25. PubMed ID: 1207877
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hemodynamic effects of beta-blocking agents].
    Bensaid J; Ourbak P; Rocha P; Renais J; Scebat L; Lenegre J
    Coeur Med Interne; 1973; 12(2):285-97. PubMed ID: 4593195
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparison of the effects of propranolol, practolol, oxyprenolol and L.B. 46 on myocardial contractility].
    Adamska-Dyniewska H
    Wiad Lek; 1973 Apr; 26(7):603-8. PubMed ID: 4144788
    [No Abstract]   [Full Text] [Related]  

  • 19. Human blood platelets as cellular models for investigation of membrane active drugs: beta-adrenergic blocking agents.
    Lemmer B; Wiethold G; Hellenbrecht D; Bak IJ; Grobecker H
    Naunyn Schmiedebergs Arch Pharmacol; 1972; 275(3):299-313. PubMed ID: 4143918
    [No Abstract]   [Full Text] [Related]  

  • 20. Blockade of 5-hydroxytryptamine receptors in the central nervous system by beta-adrenoceptor antagonists.
    Weinstock M; Weiss C; Gitter S
    Neuropharmacology; 1977 Apr; 16(4):273-6. PubMed ID: 16230
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.